Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Imagilin Technology
Frederick, Maryland, United Statesimagilin.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Imagilin has developed a patented, plant-based, non-spore forming probiotic strain that can withstand high temperatures (up to 185℉/85℃) and stomach acids, with demonstrated stability at room temperature for up to two years
- Therapeutic areas
- ImmunologyOtherGastroenterology
- Modalities
- Live biotherapeutic product therapy
- Industry
- Non-Drug Biotech
02
Partnerships
Walter Reed Army Institute of ResearchUnited States Department of Agriculture (Beltsville)University of Maryland College ParkUniversity of Maryland School of MedicineNorth Texas UniversityMarion Scott Dupont Equine Medical CenterVirginia Polytechnic InstituteHood CollegeMerimax (Brazilian biotechnology company)
Beyond the preview
Go deeper on Imagilin Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Imagilin Technology.